JoVE Visualize What is visualize?
Stop Reading. Start Watching.
Advanced Search
Stop Reading. Start Watching.
Regular Search
Find video protocols related to scientific articles indexed in Pubmed.
Effects of doxazosin as the third agent on morning hypertension and position-related blood pressure changes in diabetic patients with chronic kidney disease.
Clin. Exp. Hypertens.
PUBLISHED: 05-29-2014
Show Abstract
Hide Abstract
Abstract We conducted a prospective study to assess the effects of doxazosin, as the third agent, on morning and position-related blood pressure (BP) in 77 diabetic patients with chronic kidney disease, who were allocated randomly to doxazosin and diuretics groups. Doxazosin decreased morning BP but diuretics could not decrease pre-awakening diastolic BP. Only doxazosin improved sympathovagal balance. Doxazosin and diuretics decreased standing and sitting BP but only doxazosin improved sympathovagal balance regardless of body positions. Doxazosin did not decrease absolute BP changes shortly after standing. In diabetic patients, doxazosin decreased morning BP through improving sympathovagal balance without causing significant orthostatic hypotension (ClinicalTrials.gov number, NCT00295555).
Related JoVE Video
Impaired nitric oxide production and increased blood pressure in systemic heterozygous ATP2B1 null mice.
J. Hypertens.
PUBLISHED: 05-09-2014
Show Abstract
Hide Abstract
In the 'Millennium Genome Project', we identified ATP2B1 as a gene responsible for hypertension through single-nucleotide polymorphism analysis. The ATP2B1 gene encodes the plasma membrane calcium ATPase isoform 1, which contributes to the maintenance of intracellular calcium homeostasis by removing calcium ions.
Related JoVE Video
Efficacy of cyclosporine combination therapy for new-onset minimal change nephrotic syndrome in adults.
Clin. Exp. Nephrol.
PUBLISHED: 04-10-2014
Show Abstract
Hide Abstract
Cyclosporine and prednisolone combination therapy has been used in the treatment of minimal change nephrotic syndrome (MCNS). However, few studies have evaluated the efficacy of cyclosporine combined with intravenous methylprednisolone pulse therapy (MPT) as a first-line treatment for new-onset MCNS. We conducted a retrospective clinical study to evaluate the efficacy and safety of cyclosporine combined with MPT and oral prednisolone for new-onset MCNS in adults.
Related JoVE Video
Loss of Amino Acids Into Dialysate During Hemodialysis Using Hydrophilic and Nonhydrophilic Polyester-Polymer Alloy and Polyacrylonitrile Membrane Dialyzers.
Ther Apher Dial
PUBLISHED: 11-10-2013
Show Abstract
Hide Abstract
During hemodialysis, amino acid loss through the dialysate remained a significant problem and was not clear in some dialyzers; therefore, we investigated amino acid loss with hydrophilic and nonhydrophilic polyester-polymer alloy membranes and polyacrylonitrile membranes. Nine maintenance hemodialysis patients were studied to assess amino acid loss during hemodialysis with the three membranes. Total amino acid losses were 85.7?±?27.2?mg/L, 83.3?±?16.1?mg/L, and 72.1?±?22.5?mg/L with the hydrophilic, nonhydrophilic polyester-polymer alloy, and polyacrylonitrile membranes, respectively. Amino acid losses were greater with the hydrophilic membrane compared with the polyacrylonitrile membrane for ornithine (2.0?±?0.6 vs. 1.4?±?0.4?mg/L, P?=?0.025), phenylalanine (2.4?±?0.9 vs. 1.8?±?0.8?mg/L, P?=?0.012), and tryptophan (0.6?±?0.2 vs. 0.4?±?0.2?mg/L, P?=?0.023). Amino acid losses were greater with the nonhydrophilic membrane than with the polyacrylonitrile membrane for ornithine (2.0?±?0.4 vs. 1.4?±?0.4?mg/L, P?=?0.017), phenylalanine (2.3?±?0.5 vs. 1.8?±?0.8?mg/L, P?=?0.018), tryptophan (0.7?±?0.2 vs. 0.4?±?0.2?mg/L, P?=?0.003), and cystine (3.2?±?0.7 vs. 2.0?±?0.7?mg/L, P?=?0.005). In conclusion, greater losses of ornithine, phenylalanine, tryptophan, and cystine were observed with polyester-polymer alloy than with polyacrylonitrile membranes during hemodialysis. Constant attention should be paid to the amino acid loss profile to improve nutritional control in hemodialysis patients.
Related JoVE Video
Angiotensin receptor blocker (ARB)-diuretic versus ARB-calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy.
Clin. Exp. Hypertens.
PUBLISHED: 07-12-2013
Show Abstract
Hide Abstract
Abstract Diuretics or calcium channel blockers (CCBs) are used concomitantly with an angiotensin II receptor blocker (ARB). However, it is not established which ARB-based combination therapy is the most effective and safe. This prospective randomized open-label study compared the efficacy and safety of a fixed-dose tablet of losartan (LST)-hydrochlorothiazide (HCTZ) (n?=?99) and LST-amlodipine (AML) (n?=?77) in Japanese patients whose hypertension was uncontrolled by ARB monotherapy. Blood pressure changed similarly over the 12-month study period. Only LST-HCTZ significantly increased serum uric acid (SUA) in patients with low baseline SUA (<5.6?mg/dL) but not in patients with high baseline SUA.
Related JoVE Video
Long-term efficacy and safety of the small-sized ?2-microglobulin adsorption column for dialysis-related amyloidosis.
Ther Apher Dial
PUBLISHED: 05-25-2011
Show Abstract
Hide Abstract
Dialysis-related amyloidosis (DRA) is one of the major complications often seen in long-term dialysis patients, and is one of the factors that decreases quality of life. ?2-microglobulin (?2-m) is considered to be a major pathogenic factor in dialysis-related amyloidosis. The Lixelle adsorbent column, with various capacities, has been developed to adsorb ?2-m from the circulating blood of patients with dialysis-related amyloidosis. Using a minimum type of ?2-m-adsorbing column (Lixelle S-15), we evaluated its therapeutic efficacy and safety in dialysis patients. Seventeen hemodialysis patients with DRA were treated with the S-15 column for one year. Treatment was performed three times a week in this study. During the study period, pinch strength, visual analog scale for joint pain, and activities of daily living were evaluated every three months, and blood sampling was performed every six months. After one years treatment with the S-15 column, the ?2-m level decreased from 29.3±9.6mg/L to 24.7±5.1mg/L (P<0.05), and the high sensitive C-reactive protein level decreased from 2996±4380ng/mL to 1292±1774ng/mL. After one year of S-15 column use, pinch strength increased from 5.9±3.0pounds to 7.2±3.2pounds (P<0.05), and the visual analog scale for joint pain and activities of daily living score also improved. Long-term use of the Lixelle S-15 column is safe and effective for improvement of quality of life in chronic dialysis patients. Improvement of chronic inflammation may be one of the mechanisms through which the beneficial effects of the column is effected.
Related JoVE Video
Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy.
Ren Fail
PUBLISHED: 06-15-2010
Show Abstract
Hide Abstract
Small dense low-density lipoprotein (LDL) plays an important role in glomerular injury through conversion to an oxidatively modified form of LDL. However, few studies have evaluated the effects of antilipidemic agents on the LDL particle size and renal function in hyperlipidemic patients with nondiabetic nephropathy.
Related JoVE Video
Silent brain infarction and rapid decline of kidney function in patients with CKD: a prospective cohort study.
Am. J. Kidney Dis.
PUBLISHED: 03-01-2010
Show Abstract
Hide Abstract
Several reports have found that chronic kidney disease (CKD) is an independent risk factor for stroke. However, little is known about whether cerebrovascular disease conversely predicts the outcome of kidney function. In view of the similarities between vascular beds of the kidney and brain, we hypothesized that silent brain infarction (SBI) could reflect the degree of injury in renal small vessels and predict the risk of progression of kidney disease.
Related JoVE Video
Loss of nocturnal decline of blood pressure in non-diabetic patients with nephrotic syndrome in the early and middle stages of chronic kidney disease.
Hypertens. Res.
PUBLISHED: 03-20-2009
Show Abstract
Hide Abstract
In non-diabetic patients with nephrotic syndrome (NS) at early stages of chronic kidney disease, it remains unclear whether the degree of proteinuria affects the nocturnal blood pressure (BP) dip. We evaluated the relationship among circadian BP rhythm, proteinuria and hypoalbuminemia in these patients. We also evaluated the autonomic nervous activity. Twenty-four-hour BP was measured in NS patients (8 men and 13 women; mean age, 58.5+/-14.8 years) and age- and sex-matched normal subjects (11 men and 13 women; mean age, 54.3+/-18.2 years) as controls. Serum albumin and urinary protein concentrations were measured. Power spectral analysis of the heart rate was performed, and the high frequency (HF) and low frequency (LF) components were calculated as indices of sympathovagal balance. There were no differences in waking BP between the NS and the control groups (131+/-13/78+/-9 vs. 130+/-17/76+/-7 mm Hg; P>0.05). However, sleeping BP was significantly higher in the NS group than in the control group (127+/-18/75+/-9 vs. 115+/-14/66+/-7 mm Hg; P<0.05). Sleeping/waking BP ratios were higher in the NS group than in the control group (P<0.01). In the NS group, these ratios correlated significantly with serum albumin level (r=-0.54, P=0.011 for systolic BP; r=-0.48, P=0.030 for diastolic BP) and urinary protein excretion (r=0.47, P=0.027 for systolic BP; r=0.60, P=0.003 for diastolic BP). Both HF components and LF/HF ratios were not significantly different between the two groups. In non-diabetic NS patients, loss of nocturnal BP reduction correlates with proteinuria and hypoalbuminemia but not with circadian autonomic nervous rhythm.
Related JoVE Video
Relationship between silent brain infarction and chronic kidney disease.
Nephrol. Dial. Transplant.
PUBLISHED: 02-28-2009
Show Abstract
Hide Abstract
The presence of silent brain infarction (SBI) increases the risk of symptomatic stroke and dementia. The association between SBI and chronic kidney disease (CKD) has not been clarified. Moreover, little is known about what factors are related to SBI in CKD patients and whether the prevalence of SBI differs in CKD stage or cause of CKD.
Related JoVE Video
Evaluation of renal function and proteinuria based on mass health examinations in young Japanese obese adults.
Clin. Exp. Nephrol.
PUBLISHED: 02-16-2009
Show Abstract
Hide Abstract
Although obesity is recognized to be a risk factor for chronic kidney disease (CKD), few studies have reported the association between obesity and CKD in the young population. We investigated the relationship between obesity and renal function including proteinuria in young Japanese.
Related JoVE Video
Effect of renin-angiotensin system inhibitor on residual glomerular filtration rate in hemodialysis patients.
Ther Apher Dial
Show Abstract
Hide Abstract
Residual renal function preservation in patients with renal failure has been shown to be related to better outcomes not only in the pre-dialysis phase but also after hemodialysis initiation. However, the effect of factors such as antihypertensive agents on residual renal function preservation has not been investigated adequately in prevalent hemodialysis patients. This study examined factors related to the rate of residual renal function preservation in 1-year hemodialysis patients who had residual renal function. We enrolled 191 consecutive maintenance hemodialysis patients who underwent hemodialysis for 1 year and maintained a urine output of more than 200 mL/day, to assess residual renal function loss. The rate of residual renal function loss was 19.9%. Multivariate analysis using residual renal function as the dependent variable revealed significant independent relationships with renin-angiotensin system inhibitor use (hazard ratio, 0.438; P = 0.027), history of cardiovascular disease (hazard ratio, 2.475; P = 0.024), and rate of weight gain between dialysis sessions (hazard ratio, 1.348; P = 0.013). No relationship was observed with calcium channel blocker use. Renin-angiotensin system inhibitor use, rate of body weight gain between dialysis sessions, and cardiovascular diseases are independently associated with residual renal function preservation in patients with residual renal function after 1 year of hemodialysis. A further intervention study is required to investigate whether treatment with renin-angiotensin system inhibitors and suppression of body weight gain preserves residual renal function for a longer time in hemodialysis patients.
Related JoVE Video
Effects of carvedilol as third-line add-on therapy on blood pressure and glucose metabolism in type 2 diabetic patients with chronic renal disease stage 3 and above.
Kidney Blood Press. Res.
Show Abstract
Hide Abstract
We evaluated the effect of coadministration of ?-blocker (carvedilol) as the third agent with angiotensin II receptor blockers (ARB) and calcium channel blockers (CCB) on blood pressure (BP) regulation and glucose metabolism.
Related JoVE Video
Mice lacking hypertension candidate gene ATP2B1 in vascular smooth muscle cells show significant blood pressure elevation.
Hypertension
Show Abstract
Hide Abstract
We reported previously that ATP2B1 was one of the genes for hypertension receptivity in a large-scale Japanese population, which has been replicated recently in Europeans and Koreans. ATP2B1 encodes the plasma membrane calcium ATPase isoform 1, which plays a critical role in intracellular calcium homeostasis. In addition, it is suggested that ATP2B1 plays a major role in vascular smooth muscle contraction. Because the ATP2B1 knockout (KO) mouse is embryo-lethal, we generated mice with vascular smooth muscle cell-specific KO of ATP2B1 using the Cre-loxP system to clarify the relationship between ATP2B1 and hypertension. The KO mice expressed significantly lower levels of ATP2B1 mRNA and protein in the aorta compared with control mice. KO mice showed significantly higher systolic blood pressure as measured by tail-cuff method and radiotelemetric method. Similar to ATP2B1, the expression of the Na(+)-Ca(2+) exchanger isoform 1 mRNA was decreased in vascular smooth muscle cells of KO mice. However, ATP2B4 expression was increased in KO mice. The cultured vascular smooth muscle cells of KO mice showed increased intracellular calcium concentration not only in basal condition but also in phenylephrine-stimulated condition. Furthermore, phenylephrine-induced vasoconstriction was significantly increased in vascular rings of the femoral artery of KO mice. These results suggest that ATP2B1 plays important roles in the regulation of blood pressure through alteration of calcium handling and vasoconstriction in vascular smooth muscle cells.
Related JoVE Video

What is Visualize?

JoVE Visualize is a tool created to match the last 5 years of PubMed publications to methods in JoVE's video library.

How does it work?

We use abstracts found on PubMed and match them to JoVE videos to create a list of 10 to 30 related methods videos.

Video X seems to be unrelated to Abstract Y...

In developing our video relationships, we compare around 5 million PubMed articles to our library of over 4,500 methods videos. In some cases the language used in the PubMed abstracts makes matching that content to a JoVE video difficult. In other cases, there happens not to be any content in our video library that is relevant to the topic of a given abstract. In these cases, our algorithms are trying their best to display videos with relevant content, which can sometimes result in matched videos with only a slight relation.